Fewer Versus More Neoadjuvant Chemoimmunotherapy Cycles in Resectable Esophageal Squamous Cell Carcinoma
This retrospective propensity-matched analysis suggests that 1–2 and 3–4 cycles of neoadjuvant paclitaxel, nedaplatin, and PD-1 inhibitor yield similar recurrence-free survival and safety, informing cycle-number decisions but not settling them.
📅 Journal publication: Aug 3, 2026·Last updated: Nov 3, 2026
Neoadjuvant cycles in esophageal cancer: flexibility or necessity?
Determining optimal neoadjuvant chemotherapy cycles for esophageal squamous cell carcinoma (ESCC) can enhance treatment efficacy and patient outcomes. Post-matching, there was no significant difference in objective response rate (ORR) or pathological complete response (pCR) between 1-2 and 3-4 cycles; both had similar safety profiles. This study suggests no clear advantage of 3-4 cycles over 1-2 cycles of neoadjuvant chemotherapy combined with immunotherapy in ESCC, supporting flexibility in cycle number based on patient factors. 1-2 and 3-4 cycles of neoadjuvant chemotherapy plus immunotherapy show similar efficacy and safety in ESCC.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Lv H, Wang Z, Su C, Wang H, Chen B, Gai C, Liu Y, Ding W, Wang M, Sun K, Zhang F, Zhu Y, Li Z, Tian Z
Citation:Lv H, Wang Z, Su C, et al. Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study. World journal of surgical oncology. 2026;24(1). doi:10.1186/s12957-026-04514-0